Login to Your Account



Biogen, Elan Planning Antegren Filing In MS With One-Year Data

By Kim Coghill


Thursday, February 19, 2004
Biogen Idec Inc. and partner Elan Corp. plc gained value Wednesday after telling Wall Street they intend to file the Antegren application for multiple sclerosis based on one-year data, as opposed to waiting for the traditional two-year data set to be completed. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription